Stonepine Capital Management LLC acquired a new position in shares of Aytu BioPharma Inc. (NASDAQ:AYTU – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 912,921 shares of the company’s stock, valued at approximately $1,962,780,000. Aytu BioPharma comprises approximately 1.1% of Stonepine Capital Management LLC’s portfolio, making the stock its 28th largest holding. Stonepine Capital Management LLC owned about 8.51% of Aytu BioPharma at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of AYTU. BlackRock Inc. bought a new stake in shares of Aytu BioPharma during the second quarter worth about $49,000. Rothschild Wealth LLC acquired a new position in shares of Aytu BioPharma during the fourth quarter worth $52,000. Dimensional Fund Advisors LP bought a new stake in shares of Aytu BioPharma in the third quarter worth $58,000. XTX Topco Ltd acquired a new stake in Aytu BioPharma in the fourth quarter valued at $67,000. Finally, DRW Securities LLC bought a new position in Aytu BioPharma during the 4th quarter worth $76,000. 33.49% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms have commented on AYTU. Ascendiant Capital Markets upped their price target on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.75.
Aytu BioPharma Trading Down 2.6%
NASDAQ AYTU opened at $2.24 on Friday. The stock has a market capitalization of $24.04 million, a P/E ratio of -0.49 and a beta of 0.25. The business has a 50 day simple moving average of $2.24 and a 200 day simple moving average of $2.36. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.12 and a quick ratio of 1.00. Aytu BioPharma Inc. has a one year low of $1.65 and a one year high of $3.07.
Aytu BioPharma Company Profile
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.
Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.
Featured Stories
- Five stocks we like better than Aytu BioPharma
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding AYTU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aytu BioPharma Inc. (NASDAQ:AYTU – Free Report).
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.